Gallbladder adenoma - Revision history

Michael at 14:50, 15 August 2024

2024-08-15T14:50:19Z

← Older revision		Revision as of 14:50, 15 August 2024
Line 18:		Line 18:
	\| Site = [[gallbladder]]		\| Site = [[gallbladder]]
	\| Assdx =		\| Assdx =
	\| Syndromes =		\| Syndromes = [[familial adenomatous polyposis]], [[Peutz-Jeghers syndrome]]
	\| Clinicalhx =		\| Clinicalhx =
	\| Signs =		\| Signs =

Michael at 14:49, 15 August 2024

2024-08-15T14:49:28Z

← Older revision		Revision as of 14:49, 15 August 2024
Line 7:		Line 7:
	\| Micro =		\| Micro =
	\| Subtypes =		\| Subtypes =
	\| LMDDx = [[gallbladder ~~dysplasia~~]], [[~~adenocarcinoma of the gallbladder~~]]		\| LMDDx = [[adenocarcinoma of the gallbladder]], reactive changes - as may be seen in [[acute cholecystitis]]
	\| Stains =		\| Stains =
	\| IHC =		\| IHC =

Michael at 14:48, 15 August 2024

2024-08-15T14:48:06Z

← Older revision		Revision as of 14:48, 15 August 2024
Line 14:		Line 14:
	\| IF =		\| IF =
	\| Gross =		\| Gross =
	\| Grossing = [[~~gallbadder~~ grossing]]		\| Grossing = [[gallbladder grossing]]
	\| Staging =		\| Staging =
	\| Site = [[gallbladder]]		\| Site = [[gallbladder]]

Michael: +infobox

2024-08-15T14:47:52Z

+infobox

← Older revision		Revision as of 14:47, 15 August 2024
Line 1:		Line 1:
			{{ Infobox diagnosis
			\| Name = {{PAGENAME}}
			\| Image =
			\| Width =
			\| Caption =
			\| Synonyms =
			\| Micro =
			\| Subtypes =
			\| LMDDx = [[gallbladder dysplasia]], [[adenocarcinoma of the gallbladder]]
			\| Stains =
			\| IHC =
			\| EM =
			\| Molecular =
			\| IF =
			\| Gross =
			\| Grossing = [[gallbadder grossing]]
			\| Staging =
			\| Site = [[gallbladder]]
			\| Assdx =
			\| Syndromes =
			\| Clinicalhx =
			\| Signs =
			\| Symptoms =
			\| Prevalence = uncommon
			\| Bloodwork =
			\| Rads =
			\| Endoscopy =
			\| Prognosis =
			\| Other =
			\| ClinDDx =
			\| Tx =
			}}
	'''Gallbladder adenoma''' is a pre-malignant lesion of the [[gallbladder]].		'''Gallbladder adenoma''' is a pre-malignant lesion of the [[gallbladder]].

Michael at 22:30, 9 October 2021

2021-10-09T22:30:09Z

← Older revision		Revision as of 22:30, 9 October 2021
Line 29:		Line 29:

	===Grading dysplasia===		===Grading dysplasia===
	Low grade dysplasia:<ref name=pmid33629395>{{cite journal \|~~vauthors~~=Roa JC, Basturk O, Adsay V \|title=Dysplasia and carcinoma of the gallbladder: pathological evaluation, sampling, differential diagnosis and clinical implications \|journal=Histopathology \|volume=79 \|issue=1 \|pages=2–19 \|date=July 2021 \|pmid=33629395 \|doi=10.1111/his.14360 \|url=}}</ref>		Low grade dysplasia:<ref name=pmid33629395>{{cite journal \|authors=Roa JC, Basturk O, Adsay V \|title=Dysplasia and carcinoma of the gallbladder: pathological evaluation, sampling, differential diagnosis and clinical implications \|journal=Histopathology \|volume=79 \|issue=1 \|pages=2–19 \|date=July 2021 \|pmid=33629395 \|doi=10.1111/his.14360 \|url=}}</ref>
	*Surface epithelium changes: hyperchromasia, pseudostratification, elongated nuclei; nuclei stratified/confined mainly to lower aspect of the epithelium.		*Surface epithelium changes: hyperchromasia, pseudostratification, elongated nuclei; nuclei stratified/confined mainly to lower aspect of the epithelium.
	High grade dysplasia:<ref name=pmid33629395/>		High grade dysplasia:<ref name=pmid33629395/>

Michael: /* Grading dysplasia */

2021-10-01T20:51:49Z

Grading dysplasia

← Older revision		Revision as of 20:51, 1 October 2021
Line 30:		Line 30:
	===Grading dysplasia===		===Grading dysplasia===
	Low grade dysplasia:<ref name=pmid33629395>{{cite journal \|vauthors=Roa JC, Basturk O, Adsay V \|title=Dysplasia and carcinoma of the gallbladder: pathological evaluation, sampling, differential diagnosis and clinical implications \|journal=Histopathology \|volume=79 \|issue=1 \|pages=2–19 \|date=July 2021 \|pmid=33629395 \|doi=10.1111/his.14360 \|url=}}</ref>		Low grade dysplasia:<ref name=pmid33629395>{{cite journal \|vauthors=Roa JC, Basturk O, Adsay V \|title=Dysplasia and carcinoma of the gallbladder: pathological evaluation, sampling, differential diagnosis and clinical implications \|journal=Histopathology \|volume=79 \|issue=1 \|pages=2–19 \|date=July 2021 \|pmid=33629395 \|doi=10.1111/his.14360 \|url=}}</ref>
	*Surface epithelium changes: ~~gyperchromasia~~, pseudostratification, elongated nuclei; nuclei ~~stratfied~~/confined mainly to lower aspect of the epithelium.		*Surface epithelium changes: hyperchromasia, pseudostratification, elongated nuclei; nuclei stratified/confined mainly to lower aspect of the epithelium.
	High grade dysplasia:<ref name=pmid33629395/>		High grade dysplasia:<ref name=pmid33629395/>
	*Diffuse and severe (cytologic) atypia: nuclei no long stratified.		*Diffuse and severe (cytologic) atypia: nuclei no long stratified.

Michael: /* Grading dysplasia */

2021-10-01T20:48:43Z

Grading dysplasia

← Older revision		Revision as of 20:48, 1 October 2021
Line 32:		Line 32:
	*Surface epithelium changes: gyperchromasia, pseudostratification, elongated nuclei; nuclei stratfied/confined mainly to lower aspect of the epithelium.		*Surface epithelium changes: gyperchromasia, pseudostratification, elongated nuclei; nuclei stratfied/confined mainly to lower aspect of the epithelium.
	High grade dysplasia:<ref name=pmid33629395/>		High grade dysplasia:<ref name=pmid33629395/>
	**Diffuse and severe (cytologic) atypia: nuclei no long stratified.		*Diffuse and severe (cytologic) atypia: nuclei no long stratified.

	===Images===		===Images===

Michael: /* Microscopic */

2021-10-01T20:48:29Z

Microscopic

← Older revision		Revision as of 20:48, 1 October 2021
Line 22:		Line 22:
	Notes:		Notes:
	*Low grade dysplasia should prompt targeted sampling and review.<ref name=uscap2017_akki/>		*Low grade dysplasia should prompt targeted sampling and review.<ref name=uscap2017_akki/>
	*Gallbladders with high grade dysplasia should be [[submitted in total]] to exclude [[gallbladder adenocarcinoma]].<ref name=uscap2017_akki>Akki ''et al.'' (2017) "Detecting Incidental Gallbladder Adenocarcinoma: When to Submit the Entire Gallbladder". Available at: [http://www.abstracts2view.com/uscap17/view.php?nu=USCAP17L_2016 http://www.abstracts2view.com/uscap17/view.php?nu=USCAP17L_2016]. United States and Canadian Academy of Pathology Annual Meeting. Accessed on: April 9, 2017.</ref>		*Gallbladders with high grade dysplasia should be [[submitted in total]] to exclude [[gallbladder adenocarcinoma]].<ref name=uscap2017_akki>Akki ''et al.'' (2017) "Detecting Incidental Gallbladder Adenocarcinoma: When to Submit the Entire Gallbladder". Available at: [http://www.abstracts2view.com/uscap17/view.php?nu=USCAP17L_2016 http://www.abstracts2view.com/uscap17/view.php?nu=USCAP17L_2016]. United States and Canadian Academy of Pathology Annual Meeting. Accessed on: April 9, 2017.</ref><ref name=pmid33629395/>

	~~Grading:~~<ref name=pmid33629395>{{cite journal \|vauthors=Roa JC, Basturk O, Adsay V \|title=Dysplasia and carcinoma of the gallbladder: pathological evaluation, sampling, differential diagnosis and clinical implications \|journal=Histopathology \|volume=79 \|issue=1 \|pages=2–19 \|date=July 2021 \|pmid=33629395 \|doi=10.1111/~~his.14360 \|url=}}</ref~~>
	*Low-grade.
	*High-grade.

	DDx:		DDx:
	*[[Gallbladder adenocarcinoma]].		*[[Gallbladder adenocarcinoma]].
	*Reactive changes.		*Reactive changes.

			===Grading dysplasia===
			Low grade dysplasia:<ref name=pmid33629395>{{cite journal \|vauthors=Roa JC, Basturk O, Adsay V \|title=Dysplasia and carcinoma of the gallbladder: pathological evaluation, sampling, differential diagnosis and clinical implications \|journal=Histopathology \|volume=79 \|issue=1 \|pages=2–19 \|date=July 2021 \|pmid=33629395 \|doi=10.1111/his.14360 \|url=}}</ref>
			*Surface epithelium changes: gyperchromasia, pseudostratification, elongated nuclei; nuclei stratfied/confined mainly to lower aspect of the epithelium.
			High grade dysplasia:<ref name=pmid33629395/>
			**Diffuse and severe (cytologic) atypia: nuclei no long stratified.

	===Images===		===Images===

Michael: /* Microscopic */

2021-10-01T20:41:56Z

Microscopic

← Older revision		Revision as of 20:41, 1 October 2021
Line 23:		Line 23:
	*Low grade dysplasia should prompt targeted sampling and review.<ref name=uscap2017_akki/>		*Low grade dysplasia should prompt targeted sampling and review.<ref name=uscap2017_akki/>
	*Gallbladders with high grade dysplasia should be [[submitted in total]] to exclude [[gallbladder adenocarcinoma]].<ref name=uscap2017_akki>Akki ''et al.'' (2017) "Detecting Incidental Gallbladder Adenocarcinoma: When to Submit the Entire Gallbladder". Available at: [http://www.abstracts2view.com/uscap17/view.php?nu=USCAP17L_2016 http://www.abstracts2view.com/uscap17/view.php?nu=USCAP17L_2016]. United States and Canadian Academy of Pathology Annual Meeting. Accessed on: April 9, 2017.</ref>		*Gallbladders with high grade dysplasia should be [[submitted in total]] to exclude [[gallbladder adenocarcinoma]].<ref name=uscap2017_akki>Akki ''et al.'' (2017) "Detecting Incidental Gallbladder Adenocarcinoma: When to Submit the Entire Gallbladder". Available at: [http://www.abstracts2view.com/uscap17/view.php?nu=USCAP17L_2016 http://www.abstracts2view.com/uscap17/view.php?nu=USCAP17L_2016]. United States and Canadian Academy of Pathology Annual Meeting. Accessed on: April 9, 2017.</ref>

			Grading:<ref name=pmid33629395>{{cite journal \|vauthors=Roa JC, Basturk O, Adsay V \|title=Dysplasia and carcinoma of the gallbladder: pathological evaluation, sampling, differential diagnosis and clinical implications \|journal=Histopathology \|volume=79 \|issue=1 \|pages=2–19 \|date=July 2021 \|pmid=33629395 \|doi=10.1111/his.14360 \|url=}}</ref>
			*Low-grade.
			*High-grade.

	DDx:		DDx:

Michael: /* See also */

2017-10-30T14:08:18Z

← Older revision		Revision as of 14:08, 30 October 2017
Line 41:		Line 41:
	==See also==		==See also==
	*[[Gallbladder]].		*[[Gallbladder]].
			*[[Intestinal metaplasia of the gallbladder]].

	==References==		==References==